Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1043-1049

  Chan, Annie ^a   Leung, Loh Shan ^a   Blumenkranz, Mark S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone; Macular edema; Ozurdex

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR;

BIOCOMPATIBILITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CONJUNCTIVAL HEMORRHAGE; DRUG APPROVAL; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EYE IRRITATION; EYE PAIN; HUMAN; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; NONHUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; REVIEW; SINGLE DRUG DOSE; UNITED STATES; VISUAL IMPAIRMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 79961243594     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S13775     Document Type: Review

References (28)

1. Rogers S, McIntosh RL, Journ GD, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313-319.
2. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282. \1-\2.^p
3. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-1433.
4. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears Ml, Tarkkanen A, editors. Surgical Pharmacology of the Eye. New York: Raven Press, 1985:83-133.
5. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101-1114.
6. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
7. Edelman JL. Differentiating intraocular glucocor ticoids. Ophthalmologica. 2010;224(Suppl 1):25-30.
8. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2005;243:1186-1189.
9. Chang-Lin JE, Attar M, Acheampong AA. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-86.
10. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010;27:117-134.
11. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23:253-281.
12. Haller JA, Bandello F, Belfort R, et al. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmol. 2010;117: 1134-1146.
13. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology. 2010;117:1102-1112.
14. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology. 2010;117:1124-1133.
15. Visscher GE, Robison RL, Maulding HV, et al. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res. 1985;19:349-365.
16. Moritera T, Ogura Y, Honda Y, et al. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32:1785-1790.
17. Fialho SL, Rego MB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31:525-534.
18. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol. 1991;15:233-235.
19. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259-266.
20. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.
21. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29:46-51.
22. Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2003;121:1297-1302.
23. Awdeh RM, Elsing SH, Deramo VA, et al. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol.2010;94:319-323.
24. Chang MA, Fine HF, Bass E, et al. Patients' preferences in choosing therapy for retinal vein occlusions. Retina. 2007;27:789-797.
25. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1102el-1112el.
26. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1124el-1133el.
27. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
28. Mason JO, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes. Retina. 2004;24:900-904.